Marie Skłodowska-Curie Doctoral Network NANOREMEDI-programme in “Functional Nano-Scaffolds for Regenerative Medicine” stems from six Doctoral Courses/Schools at six beneficiary institutions, providing research and training in the field of nanomaterials for Regenerative Medicine. An active contribution of enterprises in training activities is a relevant feature of the programme.
Beneficiaries (Doctorate Courses/Schools): University of Milan (Pharmaceutical Sciences), ITALY – Coordinating University; Universitat Politècnica de Catalunya (Polymers and Biopolymers) SPAIN; The Hebrew University Jerusalem (School of Chemistry), ISRAEL; Université de Montpellier (Balard Chemical Sciences doctoral school), FRANCE; University of Pavia (Bioengineering, Bioinformatics & Health Technologies), ITALY; IC nanoGUNE (Materials Physics; delivered by University of the Basque Country - Associated Partner linked to NANOGUNE beneficiary), SPAIN.
Associated partners for secondments activities: Bayer Health Care Pharmaceuticals – ITALY; Edelweiss Connect GMBH – SWITZERLAND; Italfarmaco S.p.A. (CHEMI) – ITALY; Jacobacci & Partners – ITALY; Lynxter -FRANCE; Simune Atomistics SL – SPAIN; Ponti & Partners, SLP – SPAIN; AbMedica – ITALY; DeLama – ITALY; Officine Innovazione Srl (Deloitte) – ITALY; Genepep – FRANCE; BioBasic Europe rsl - ITALY
The scientific approach proposed by NanoReMedi Consortium is strongly multidisciplinary and will involve a number of different state-of-the-art technologies and methodologies. Expected results are:
- Generate tissue engineered vascular grafts (VGs) to replace damaged peripheral arteries
- Study stem-cell based regenerative medicine for bone and cartilage repair
- Tackle implantation failure of engeneered tissues/scaffolds
One position is available at University of Milano in research project N ESR2:
Secondments: i) nine months at Universitat Politecnica de Catalunya ii) three months of enterprise secondment at Italfarmaco.
Continue with Facebook
